In contrast, in RKO tumor cells treated with the TRAIL plus 17-AAG combination, Z-IETD-FMK exposure resulted in the levels of depleted HSP90 client proteins such as ERBB2, IKKα and AKT returning to those observed in tumor cells treated with 17-AAG alone (Fig. 5G). The gene discussed is CHUK; the disease is neoplasm.